The switch to biosimilar rituximab at UCH: 12 months on - 102017

Spotlight
Video

The switch to biosimilar rituximab at UCH: 12 months on

VJOncology has 824 videos Subscribe Here

Loading........
Description: At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months.
Content on www.vjoncology.com... and www.vjhemonc.com... from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Shared By : VJOncology
Posted on : 10/15/18
Added : 2 months ago
Category : Lymphoma